Provided are formulations, methods, and devices for providing a hydrogel. The formulations and resulting hydrogels may be used for treating various disorders, including ocular disorders. In certain embodiments, the hydrogel is formed from formulations comprising (a) a nucleo-functional polymer that is a biocompatible polyalkylene polymer substituted by (i) a plurality of OH groups, (ii) a plurality of thio-functional groups R.sup.1SH wherein R.sup.1 is an ester-containing linker, and (iii) optionally one or more OC(O)(C.sub.1-C.sub.6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer; (b) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups; and (c) one or more pharmaceutically active agents. In certain embodiments, the hydrogel is formed at a targeted sited using methods and/or devices for focal administration of the formulations and/or hydrogels described herein.

Provided are formulations, methods, and devices for providing a hydrogel. The formulations and resulting hydrogels may be used for treating various disorders, including ocular disorders. In certain embodiments, the hydrogel is formed from formulations comprising (a) a nucleo-functional polymer that is a biocompatible polyalkylene polymer substituted by (i) a plurality of OH groups, (ii) a plurality of thio-functional groups R.sup.1SH wherein R.sup.1 is an ester-containing linker, and (iii) optionally one or more OC(O)(C.sub.1-C.sub.6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer; (b) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups; and (c) one or more pharmaceutically active agents. In certain embodiments, the hydrogel is formed at a targeted sited using methods and/or devices for focal administration of the formulations and/or hydrogels described herein.

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

A multifunctional copolymeric nanoparticle, including a plurality of 1,4-diazabicyclo[2.2.2]octane (DABCO) monomers crosslinked with a plurality of bromoacetyl cystamine (BBAC) monomers. Also, each of the plurality of DABCO monomers and each of the plurality of BBAC monomers alternate in sequence. the multifunctional copolymeric nanoparticle has a formula:

##STR00001##

wherein n is an integer between 5 and 40.

A multifunctional copolymeric nanoparticle, including a plurality of 1,4-diazabicyclo[2.2.2]octane (DABCO) monomers crosslinked with a plurality of bromoacetyl cystamine (BBAC) monomers. Also, each of the plurality of DABCO monomers and each of the plurality of BBAC monomers alternate in sequence. the multifunctional copolymeric nanoparticle has a formula:

##STR00001##

wherein n is an integer between 5 and 40.

The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.

The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.

The use of a composition which comprises lignosulfonate for the prevention and treatment of pathogenic and medical disorders in humans and animals. In some embodiments the composition is substantially free of elemental sulphur. In some embodiments the lignosulfonate is radically polymerized. In some embodiments the composition is formulated as an animal feed additive or supplement. The disclosure also encompasses a method of preventing or treating a pathogenic or medical disorder in a human or animal subject by administering the composition to the subject in an effective dose to attenuate the pathogenic effect of a pathogen or other biological agent, thereby enabling the subject to mount an effective immune response to the pathogen or other biological agent. The composition can be used in the prevention or treatment of a wide range of pathogenic or medical disorders including disorders caused by microbial pathogens; disorders caused by viral pathogens; disorders caused by prions; disorders caused by protists; disorders caused by fungi; disorders caused by parasites; lung and airway disorders; bone, joint and muscle disorders; digestive disorders; hormonal disorders; cancer; auto immune disorders; neurodegenerative disorders; skin disorders; and sexual and reproductive disorders. In one particular embodiment the composition is formulated for treatment of Type 1 diabetes.

The use of a composition which comprises lignosulfonate for the prevention and treatment of pathogenic and medical disorders in humans and animals. In some embodiments the composition is substantially free of elemental sulphur. In some embodiments the lignosulfonate is radically polymerized. In some embodiments the composition is formulated as an animal feed additive or supplement. The disclosure also encompasses a method of preventing or treating a pathogenic or medical disorder in a human or animal subject by administering the composition to the subject in an effective dose to attenuate the pathogenic effect of a pathogen or other biological agent, thereby enabling the subject to mount an effective immune response to the pathogen or other biological agent. The composition can be used in the prevention or treatment of a wide range of pathogenic or medical disorders including disorders caused by microbial pathogens; disorders caused by viral pathogens; disorders caused by prions; disorders caused by protists; disorders caused by fungi; disorders caused by parasites; lung and airway disorders; bone, joint and muscle disorders; digestive disorders; hormonal disorders; cancer; auto immune disorders; neurodegenerative disorders; skin disorders; and sexual and reproductive disorders. In one particular embodiment the composition is formulated for treatment of Type 1 diabetes.